Thalidomide for treatment of refractory epilepsy

Epilepsy Research

Volumn 92, Issue 2-3, 2010, Pages 253-257

  Palencia, Guadalupe ^a   Martinez Juarez, Iris E ^a   Calderon, Alejandra ^a   Artigas, Carol ^a   Sotelo, Julio ^a  

^a NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

Author keywords

Antiepileptic drugs; Refractory epilepsy; Sedative drugs; Thalidomide

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLONAZEPAM; LAMOTRIGINE; OXCARBAZEPINE; PHENYLHYDANTOIN; PRIMIDONE; THALIDOMIDE; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID;

ADOLESCENT; ADULT; ARTICLE; ATAXIA; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG WITHDRAWAL; EPILEPSY; HUMAN; MALE; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REFRACTORY EPILEPSY; SEDATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; VERTIGO;

ANALYSIS OF VARIANCE; EPILEPSY; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; STATISTICS, NONPARAMETRIC; THALIDOMIDE;

EID: 78650178475     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2010.10.003     Document Type: Article

References (20)

1. Aguirre-Cruz L., Martinez-Moreno M., Palencia G., Mendez-Mar N., Manjarrez J., Alvarado R., et al. Protective effect of thalidomide in rats with granuloma in the cerebral amygdala and pentylenetetrazole-induced epilepsy. Clin. Immunol. 2005, 115(Suppl. 1):S84.
2. Bergstroem R.M., Bergstroem L., Putkonen P., Sainio K. The effects of thalidomide on the electrical activity of the brain in the intrauterine guinea-pig foetus. Med. Exp. Int. J. Exp. Med. 1964, 11:119-127.
3. Calabrese L., Fleischer A.B. Thalidomide: current and potential clinical applications. Am. J. Med. 2000, 108:487-495.
4. Cuadrado M.J., Karim Y., Sanna G., Smith E., Khamashta M.A., Hughes G.R. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens. Am. J. Med. 2005, 118:246-250.
5. Franks M.E., Macpherson G.R., Figg W.D. Thalidomide. Lancet 2004, 363:1802-1811.
6. Frederickson R.C., Slater I.H., Dusenberry W.E., Hewes C.R., Jones G.T., Moore R.A. A comparison of thalidomide and pentobarbital-new methods for identifying novel hypnotic drugs. J. Pharmacol. Exp. Ther. 1977, 203:240-251.
7. French J.A., Kanner A.M., Bautista J., Abou-Khalil B., Browne T., Harden C.L., et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004, 62:1261-1273.
8. French J.A. Refractory epilepsy: clinical overview. Epilepsia 2007, 48(Suppl. 1):3-7.
9. Gayatri N.A., Livingston J.H. Aggravation of epilepsy by antiepileptic drugs. Dev. Med. Child Neurol. 2006, 48:394-398.
10. Kunz W., Keller H., Muckter H. N-phthalylglutamineaure-imid: experimentelle untersuchungen an einem neuen synthetischen produkt mit sedativen eigenschaften. Arzneim-Forsch 1956, 6:426-430.
11. Lenz W., Pfeiffer R.A., Kosenow W., Hayman D.J. Thalidomide and congenital abnormalities. Lancet 1962, 279:45-46.
12. Marjanovic B.D., Stojanov L.M., Zdravkovic D.S., Kravljanac R.M., Djordjevic M.S. Rasmussen syndrome and long-term response to thalidomide. Pediatr. Neurol. 2003, 29:151-156.
13. Miller J.W., McKeon A.C., Ferrendelli J.A. Functional anatomy of pentylenetetrazol and electroshock seizures in the rat brainstem. Ann. Neurol. 1987, 22:615-621.
14. Palencia G., Calderon A., Sotelo J. Thalidomide inhibits pentylenetetrazole-induced seizures. J. Neurol. Sci. 2007, 258:128-131.
15. Parman T., Wiley M.J., Wells P.G. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat. Med. 1999, 5:582-585.
16. Ravenscroft A., Schoeman J.F., Pretorious M.L., Rickman R.C. Rasmussen's encephalitis: case presentation and discussion on the role of specific immune modulation. Brain Dev. 1998, 20:398.
17. Richardson P., Hideshima T., Anderson K. Thalidomide: emerging role in cancer medicine. Annu. Rev. Med. 2002, 53:629-657.
18. Sisodiya S. Etiology and management of refractory epilepsies. Nat. Clin. Pract. Neurol. 2007, 3:320-330.
19. Somers G.F. Pharmacological properties of thalidomide (alpha-phthalimido glutarimide), a new sedative hypnotic drug. Br. J. Pharmacol. Chemother. 1960, 15:111-116.
20. Tosi P., Zamagni E., Cellini C., Plasmati R., Cangini D., Tacchetti P., et al. Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. Eur. J. Haematol. 2005, 74:212-216.